Alkermes plc ALKS

NAS: ALKS | ISIN: IE00B56GVS15   16:36
27,21 USD (-0,15%)
(-0,15%)   16:36

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023

DUBLIN, Feb. 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 16, 2023 to discuss the company's fourth quarter and year-end 2022 financial results. Management will also discuss financial expectations for 2023 and provide an update on the company.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Bernard
Investor Relations
+1 781 873 2402

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-fourth-quarter-and-year-end-financial-results-on-feb-16-2023-301743184.html

SOURCE Alkermes plc

Alkermes plc in het nieuws

Mijn selecties